Abstract
Background: The implementation of breast cancer (BC) screening programs and diagnostics have resulted in up to 35% of BC being clinically non-palpable at diagnosis1. In our breastcenter we recently switched from wire-guided localization (WGL) to radioguided seed localization (RLS) for the localization of non-palpable tumors. RSL involves a small titanium seed (4 x 0.8mm), which is labeled with I-125 and introduced into the lesion percutaneously. The seed is then localized intraoperatively with a gamma probe. A recent meta-analysis who compared RSL vs. WGL has shown a lower rate of involved margins, a lower reoperation rate and a shorter surgical operative time with RSL but no difference in the volume of the specimens removed between the two groups2. RLS can also be used prior to systemic treatment to mark pathological lymphnodes in order to perform targeted axilla dissection and to localize non-palpable lymphnodes. We aim to describe our experience in introducing RLS in our breast center and to compare the above mentioned variables among two comparable groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
